Primary Hyperoxaluria Type 1 (PH1) Archives

FDA Greenlights First-Ever PH1 Treatment

Adults, Approvals, Children, Clinical Trials, FDA, Kidneys, Primary Hyperoxaluria Type 1 (PH1), Priority Review, R&D, Rare Pediatric Disease Priority Review Voucher, RNA Interference (RNAi), Therapeutics, Ultra Rare Diseases

The U.S. Food and Drug Administration (FDA) approved Alnylam Pharmaceuticals’ Oxlumo (lumasiran) for primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in children and adults.

Alnylam Shares Positive Trial Results for Primary Hyperoxaluria Drug

Adults, Business, Children, Clinical Trials, Genetic Mutations, Kidneys, Metabolic Disorders, Primary Hyperoxaluria Type 1 (PH1), R&D, Rare Disorders, RNAi therapeutics, Shares

Alnylam Pharmaceuticals presented complete results from the company’s ILLUMINATE-B Phase III study in children under 6 years with primary hyperoxaluria type 1 (PH1), a rare disorder affecting the kidneys.

Alnylam’s Lumasiran Shows Positive Results in Treating Rare Kidney Stone Disease

Clinical Data, Clinical Trials, Primary Hyperoxaluria Type 1 (PH1), Quality Performance Indicators, R&D, RNA Interference (RNAi)

Cambridge, Massachusetts-based Alnylam Pharmaceuticals released positive Phase III data from the ILLUMINATE-A clinical trial of lumasiran in the treatment of primary hyperoxaluria type 1 (PH1).